Company Information

    Zucara Therapeutics was founded on January 2015. The company is based in Vancouver. The number of employees in Zucara Therapeutics is less than 10. Zucara therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes.

    Here is how Zucara Therapeutics describes itself: "Zucara Therapeutics"
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          Zucara Therapeutics has received 5 rounds of venture funding. The total funding amount is around $25.3M.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        Zucara Therapeutics - Blog

                          • Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes

                          • Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes – ZT-01 Development for T2D to be Supported by Nearly $450K in Non-Dilutive Funding – Toronto, Canada, November 2, 2020 – Zucara Therapeutics Inc. (“Zucara” or the “Company”), a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose […]
                          • Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01

                          • Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01 – Phase 1 Trial to Evaluate ZT-01 for the Prevention of Insulin-Induced Hypoglycemia in Patients with Type 1 Diabetes – Toronto, Canada, September 29, 2020 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low […]
                          • Zucara Therapeutics Announces US$21 Million Series A Financing

                          • Zucara Therapeutics Announces US$21 Million Series A Financing – Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials – – Series A Financing led by the Perceptive Xontogeny Venture Fund  – Toronto, Canada, March 31, 2020 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced […]
                          • Zucara Therapeutics Presents New Data at European Association for the Study of Diabetes

                          • Dr. Richard Liggins, Chief Scientific Officer, presenting at EASD in Barcelona. TORONTO, Canada and BARCELONA, Spain: Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with Type 1 diabetes and other types of insulin-dependent diabetes, presented new findings today at the 55th Annual Meeting of the European […]
                          • Zucara Therapeutics Secures Grant from GlycoNet to Expand and Validate their Drug Therapy Model for Type 1 Diabetes to Type 2 Diabetes

                          • Toronto & Vancouver, Canada:  Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with type 1 diabetes and other types of insulin-dependent diabetes, has secured a grant of $69,000 from Canadian Glycomics Network (GlycoNet) to expand and validate the model for its lead drug candidate “ZT-01” from […]
                          • Remembering Dr. Mladen Vranic: The Outstanding Diabetes Researcher

                          • (Michael Midmer & Dr. Mladen Vranic) Dr. Mladen Vranic, a leading scientist and advocate for the advancement of diabetes research, and teacher of innumerable renowned scientists and academic leaders, helped millions of diabetic patients all over the world with his remarkable work before he passed away on June 18, 2019. Born in Croatia in 1930, […]

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *